Ruddlesden–Popper hybrid lead bromide perovskite nanosheets of phase pure n=2: Stabilized colloids stored in the solid state

Ruddlesden-Popper lead halide perovskite (RP-LHP) nano-nanostructures can be regarded as self-assembled quantum wells or superlattices of 3D perovskites with an intrinsic quantum well thickness of a single or a few (n=2-4) lead halide layers; the quantum wells are separated by organic layers. They can be scaled down to a single quantum well dimension. Here, the preparation of highly (photo)chemical and colloidal stable hybrid LHP nanosheets (NSs) of ca. 7.4 µm lateral size and 2.5 nm quantum well height (thereby presenting a deep blue emission at ca. 440 nm), is reported for the first time. The NSs are close-lying and they even interconnect when deposited on a substrate. Their synthesis is based on the use of the p-toluenesulfonic acid/dodecylamine (pTS/DDA) ligand pair and their (photo)chemical stability and photoluminescence is enhanced by adding EuBr2 nanodots (EuNDs). Strikingly, they can be preserved as a solid and stored for at least one year. The blue emissive colloid can be recovered from the solid as needed by simply dispersing the powder in toluene and then using it to prepare solid films, making them very promising candidates for manufacturing devices. © 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH

The Dark Side of Lead-Free Metal Halide Nanocrystals: Substituent-Modulated Photocatalytic Activity in Benzyl Bromide Reduction

Se describe el primer ejemplo de homo-/hetero-acoplamiento Csp3-Csp3 de haluros de bencilo promovida por un nanofotocatalizador sostenible (sin plomo), estable y eficiente, en particular nanocristales de Cs3Sb2Br9, para dar lugar a derivados de bibencilo. Las propiedades electrónicas de los sustituyentes del bromuro de bencilo y la afinidad del sustrato por la superficie del nanocristal determinan la selectividad en el acoplamiento C-C producido bajo irradiación con luz visible. El fotocatalizador, Cs3Sb2Br9 NCs, puede reutilizarse durante al menos tres ciclos, manteniendo un TON de aprox. 105.000, lo que supone una mejora sustancial del proceso de acoplamiento C-C respecto a la utilización de un catalizador como el CsPbBr3, que presenta toxicidad (presencia de plomo), y cuyo TON es 17500

Linear assembly of lead bromide-based nanoparticles inside lead(ii) polymers prepared by mixing the precursors of both the nanoparticle and the polymer

Mixing precursors of lead(ii) polymers with those of lead bromide-based nanoparticles (CH3NH3PbBr3 perovskites or PbBr2), at room temperature and in the presence of cyclohexanemethylammonium bromide, generated colloidal nanocomposites which, when deposited on a hydrophobic surface led to long, one-dimensional, ordered and well-defined architectures.status: publishe

Possible Atmospheric Diversity of Low Mass Exoplanets – Some Central Aspects

Exoplanetary science continues to excite and surprise with its rich diversity. We discuss here some key aspects potentially influencing the range of exoplanetary terrestrial-type atmospheres which could exist in nature. We are motivated by newly emerging observations, refined approaches to address data degeneracies, improved theories for key processes affecting atmospheric evolution and a new generation of atmospheric models which couple physical processes from the deep interior through to the exosphere and consider the planetary-star system as a whole. Using the Solar System as our guide we first summarize the main processes which sculpt atmospheric evolution then discuss their potential interactions in the context of exoplanetary environments. We summarize key uncertainties and consider a diverse range of atmospheric compositions discussing their potential occurrence in an exoplanetary context

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Background Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in older adults as a result of immunosenescence. We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), in young adults, and now describe the safety and immunogenicity of this vaccine in a wider range of participants, including adults aged 70 years and older. Methods In this report of the phase 2 component of a single-blind, randomised, controlled, phase 2/3 trial (COV002), healthy adults aged 18 years and older were enrolled at two UK clinical research facilities, in an age-escalation manner, into 18–55 years, 56–69 years, and 70 years and older immunogenicity subgroups. Participants were eligible if they did not have severe or uncontrolled medical comorbidities or a high frailty score (if aged ≥65 years). First, participants were recruited to a low-dose cohort, and within each age group, participants were randomly assigned to receive either intramuscular ChAdOx1 nCoV-19 (2·2 × 1010 virus particles) or a control vaccine, MenACWY, using block randomisation and stratified by age and dose group and study site, using the following ratios: in the 18–55 years group, 1:1 to either two doses of ChAdOx1 nCoV-19 or two doses of MenACWY; in the 56–69 years group, 3:1:3:1 to one dose of ChAdOx1 nCoV-19, one dose of MenACWY, two doses of ChAdOx1 nCoV-19, or two doses of MenACWY; and in the 70 years and older, 5:1:5:1 to one dose of ChAdOx1 nCoV-19, one dose of MenACWY, two doses of ChAdOx1 nCoV-19, or two doses of MenACWY. Prime-booster regimens were given 28 days apart. Participants were then recruited to the standard-dose cohort (3·5–6·5 × 1010 virus particles of ChAdOx1 nCoV-19) and the same randomisation procedures were followed, except the 18–55 years group was assigned in a 5:1 ratio to two doses of ChAdOx1 nCoV-19 or two doses of MenACWY. Participants and investigators, but not staff administering the vaccine, were masked to vaccine allocation. The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years. Humoral responses at baseline and after each vaccination until 1 year after the booster were assessed using an in-house standardised ELISA, a multiplex immunoassay, and a live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) microneutralisation assay (MNA80). Cellular responses were assessed using an ex-vivo IFN-γ enzyme-linked immunospot assay. The coprimary outcomes of the trial were efficacy, as measured by the number of cases of symptomatic, virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were by group allocation in participants who received the vaccine. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. This study is ongoing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137. Findings Between May 30 and Aug 8, 2020, 560 participants were enrolled: 160 aged 18–55 years (100 assigned to ChAdOx1 nCoV-19, 60 assigned to MenACWY), 160 aged 56–69 years (120 assigned to ChAdOx1 nCoV-19: 40 assigned to MenACWY), and 240 aged 70 years and older (200 assigned to ChAdOx1 nCoV-19: 40 assigned to MenACWY). Seven participants did not receive the boost dose of their assigned two-dose regimen, one participant received the incorrect vaccine, and three were excluded from immunogenicity analyses due to incorrectly labelled samples. 280 (50%) of 552 analysable participants were female. Local and systemic reactions were more common in participants given ChAdOx1 nCoV-19 than in those given the control vaccine, and similar in nature to those previously reported (injection-site pain, feeling feverish, muscle ache, headache), but were less common in older adults (aged ≥56 years) than younger adults. In those receiving two standard doses of ChAdOx1 nCoV-19, after the prime vaccination local reactions were reported in 43 (88%) of 49 participants in the 18–55 years group, 22 (73%) of 30 in the 56–69 years group, and 30 (61%) of 49 in the 70 years and older group, and systemic reactions in 42 (86%) participants in the 18–55 years group, 23 (77%) in the 56–69 years group, and 32 (65%) in the 70 years and older group. As of Oct 26, 2020, 13 serious adverse events occurred during the study period, none of which were considered to be related to either study vaccine. In participants who received two doses of vaccine, median anti-spike SARS-CoV-2 IgG responses 28 days after the boost dose were similar across the three age cohorts (standard-dose groups: 18–55 years, 20 713 arbitrary units [AU]/mL [IQR 13 898–33 550], n=39; 56–69 years, 16 170 AU/mL [10 233–40 353], n=26; and ≥70 years 17 561 AU/mL [9705–37 796], n=47; p=0·68). Neutralising antibody titres after a boost dose were similar across all age groups (median MNA80 at day 42 in the standard-dose groups: 18–55 years, 193 [IQR 113–238], n=39; 56–69 years, 144 [119–347], n=20; and ≥70 years, 161 [73–323], n=47; p=0·40). By 14 days after the boost dose, 208 (>99%) of 209 boosted participants had neutralising antibody responses. T-cell responses peaked at day 14 after a single standard dose of ChAdOx1 nCoV-19 (18–55 years: median 1187 spot-forming cells [SFCs] per million peripheral blood mononuclear cells [IQR 841–2428], n=24; 56–69 years: 797 SFCs [383–1817], n=29; and ≥70 years: 977 SFCs [458–1914], n=48). Interpretation ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose. Further assessment of the efficacy of this vaccine is warranted in all age groups and individuals with comorbidities. Funding UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca